Literature DB >> 27852859

Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis.

Xiaoyan Liu1,2, Christine Happel2, Joseph M Ziegelbauer3.   

Abstract

Kaposi's sarcoma is one of the most common malignancies in HIV-infected individuals. The responsible agent, Kaposi's sarcoma-associated herpesvirus (KSHV; HHV8), expresses multiple microRNAs (miRNAs), but the targets and functions of these miRNAs are not completely understood. After infection in primary endothelial cells with KSHV, growth arrest DNA damage-inducible gene 45 beta (GADD45B) is one of the most repressed genes using genomic expression profiling. GADD45B was also repressed in mRNA expression profiling experiments when KSHV miRNAs were introduced to uninfected cells. We hypothesized that KSHV miRNAs target human GADD45B to protect cells from consequences of DNA damage, which can be triggered by viral infection. Expression of GADD45B protein is induced by the p53 activator, Nutlin-3, and KSHV miRNA-K9 inhibits this induction. In addition, Nutlin-3 increased apoptosis and cell cycle arrest based on flow cytometry assays. KSHV miR-K9 protected primary endothelial cells from apoptosis and cell cycle arrest following Nutlin-3 treatment. Similar protective phenotypes were seen for targeting GADD45B with short interfering RNAs (siRNAs), as with miR-K9. KSHV miR-K9 also decreased the protein levels of cleaved caspase-3, cleaved caspase-7, and cleaved poly(ADP-ribose) polymerase (PARP). In B lymphocytes latently infected with KSHV, specific inhibitors of KSHV miR-K9 led to increased GADD45B expression and apoptosis, indicating that miR-K9 is important for reducing apoptosis in infected cells. Furthermore, ectopic expression of GADD45B in KSHV-infected cells promoted apoptosis. Together, these results identify a new miRNA target and demonstrate that KSHV miRNAs are important for protecting infected cells from DNA damage responses. IMPORTANCE: Kaposi's sarcoma-associated herpesvirus is a leading cause of cancers in individuals with AIDS. Promoting survival of infected cells is essential for maintaining viral infections. A virus needs to combat various cellular defense mechanisms designed to eradicate the viral infection. One such response can include DNA damage response factors, which can promote an arrest in cell growth and trigger cell death. We used a new approach to search for human genes repressed by small nucleic acids (microRNAs) expressed by a gammaherpesvirus (KSHV), which identified a gene called GADD45B as a target of microRNAs. Repression of GADD45B, which is expressed in response to DNA damage, benefited survival of infected cells in response to a DNA damage response. This information could be used to design new treatments for herpesvirus infections.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  DNA damage; Kaposi's sarcoma-associated herpesvirus; cell cycle; microRNA

Mesh:

Substances:

Year:  2017        PMID: 27852859      PMCID: PMC5244352          DOI: 10.1128/JVI.02045-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

2.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function.

Authors:  Huaxin Si; Erle S Robertson
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Paola Secchiero; Elisa Barbarotto; Mario Tiribelli; Carlotta Zerbinati; Maria Grazia di Iasio; Arianna Gonelli; Francesco Cavazzini; Diana Campioni; Renato Fanin; Antonio Cuneo; Giorgio Zauli
Journal:  Blood       Date:  2006-01-26       Impact factor: 22.113

Review 5.  Viruses, microRNAs, and host interactions.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

6.  Identification of growth arrest and DNA-damage-inducible gene beta (GADD45beta) as a novel tumor suppressor in pituitary gonadotrope tumors.

Authors:  Katherine A Michaelis; Aaron J Knox; Mei Xu; Katja Kiseljak-Vassiliades; Michael G Edwards; Mark Geraci; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Margaret E Wierman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

7.  Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence.

Authors:  Andrew M Leidal; David P Cyr; Richard J Hill; Patrick W K Lee; Craig McCormick
Journal:  Cell Host Microbe       Date:  2012-02-16       Impact factor: 21.023

8.  Epstein-Barr virus maintains lymphomas via its miRNAs.

Authors:  D T Vereide; E Seto; Y-F Chiu; M Hayes; T Tagawa; A Grundhoff; W Hammerschmidt; B Sugden
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

9.  Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.

Authors:  Ling Wang; Blossom Damania
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis.

Authors:  Guillaume Suffert; Georg Malterer; Jean Hausser; Johanna Viiliäinen; Aurélie Fender; Maud Contrant; Tomi Ivacevic; Vladimir Benes; Frédéric Gros; Olivier Voinnet; Mihaela Zavolan; Päivi M Ojala; Juergen G Haas; Sébastien Pfeffer
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

View more
  12 in total

1.  C19ORF66 Broadly Escapes Virus-Induced Endonuclease Cleavage and Restricts Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  William Rodriguez; Kumaraman Srivastav; Mandy Muller
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

Review 2.  KSHV microRNAs: Tricks of the Devil.

Authors:  Jie Qin; Wan Li; Shou-Jiang Gao; Chun Lu
Journal:  Trends Microbiol       Date:  2017-03-02       Impact factor: 17.079

3.  Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis.

Authors:  Tingting Li; Enguo Ju; Shou-Jiang Gao
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

4.  Cis regulation within a cluster of viral microRNAs.

Authors:  Monika Vilimova; Maud Contrant; Ramy Randrianjafy; Philippe Dumas; Endrit Elbasani; Päivi M Ojala; Sébastien Pfeffer; Aurélie Fender
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

5.  The Kaposi's sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target.

Authors:  Bizunesh Abere; Tamrat M Mamo; Silke Hartmann; Naira Samarina; Elias Hage; Jessica Rückert; Sven-Kevin Hotop; Guntram Büsche; Thomas F Schulz
Journal:  PLoS Pathog       Date:  2017-09-22       Impact factor: 6.823

6.  Nuclease escape elements protect messenger RNA against cleavage by multiple viral endonucleases.

Authors:  Mandy Muller; Britt A Glaunsinger
Journal:  PLoS Pathog       Date:  2017-08-25       Impact factor: 6.823

Review 7.  Extracellular RNA in viral-host interactions: Thinking outside the cell.

Authors:  Sarah Ressel; Adelina Rosca; Katrina Gordon; Amy H Buck
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-04-08       Impact factor: 9.957

8.  A Non-Coding RNA Network Involved in KSHV Tumorigenesis.

Authors:  Julián Naipauer; Martín E García Solá; Daria Salyakina; Santas Rosario; Sion Williams; Omar Coso; Martín C Abba; Enrique A Mesri; Ezequiel Lacunza
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

Review 9.  The Clinical Application of MicroRNAs in Infectious Disease.

Authors:  Ruth E Drury; Daniel O'Connor; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

Review 10.  MicroRNA-Related Polymorphisms in Infectious Diseases-Tiny Changes With a Huge Impact on Viral Infections and Potential Clinical Applications.

Authors:  Joel Henrique Ellwanger; Francis Maria Báo Zambra; Rafael Lima Guimarães; José Artur Bogo Chies
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.